198 related articles for article (PubMed ID: 17505730)
1. [Effects of reading, exercise and exercise combined with reading on intraocular pressure for patients sustaining primary glaucoma (open angle) or ocular hypertension, both clinically controlled with topic medication].
Medina AM; Lima NV; Santos RC; Pereira MC; Santos PM
Arq Bras Oftalmol; 2007; 70(1):115-9. PubMed ID: 17505730
[TBL] [Abstract][Full Text] [Related]
2. Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study.
Mansberger SL; Hughes BA; Gordon MO; Spaner SD; Beiser JA; Cioffi GA; Kass MA;
Arch Ophthalmol; 2007 Apr; 125(4):454-9. PubMed ID: 17420364
[TBL] [Abstract][Full Text] [Related]
3. Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication.
King AJ; Rotchford AP
JAMA Ophthalmol; 2016 Jul; 134(7):742-7. PubMed ID: 27148831
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
5. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population.
Tzamalis A; Kynigopoulos M; Chalvatzis N; Dimitrakos S; Schlote T
J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension.
Nordmann JP; Rouland JF; Mertz BP
Curr Med Res Opin; 1999; 15(2):87-93. PubMed ID: 10494491
[TBL] [Abstract][Full Text] [Related]
7. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
Diestelhorst M
Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
[TBL] [Abstract][Full Text] [Related]
8. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
9. [The glaucoma pharmacological treatment and biomechanical properties of the cornea].
Liehneová I; Karlovská S
Cesk Slov Oftalmol; 2014 Oct; 70(5):167-76. PubMed ID: 25640039
[TBL] [Abstract][Full Text] [Related]
10. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
11. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness.
Schrems WA; Schrems-Hoesl LM; Mardin CY; Horn FK; Juenemann AG; Kruse FE; Braun JM; Laemmer R
J Glaucoma; 2016 Mar; 25(3):274-80. PubMed ID: 25383467
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
[TBL] [Abstract][Full Text] [Related]
14. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
[TBL] [Abstract][Full Text] [Related]
15. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
March WF; Ochsner KI
Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
[TBL] [Abstract][Full Text] [Related]
16. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study.
Emmerich KH
Graefes Arch Clin Exp Ophthalmol; 2000 Jan; 238(1):19-23. PubMed ID: 10664047
[TBL] [Abstract][Full Text] [Related]
17. Goldmann applanation tonometry and dynamic contour tonometry after treatment with prostaglandin analog/prostamide.
Ang GS; Wells AP
J Glaucoma; 2010; 19(5):346; author reply 347. PubMed ID: 20543630
[No Abstract] [Full Text] [Related]
18. [Mechanisms, clinical profile and role of prostaglandin and prostamide analogues in antiglaucomatous therapy].
Yu A; Welge-Lüßen U
Klin Monbl Augenheilkd; 2013 Feb; 230(2):127-32. PubMed ID: 23335086
[TBL] [Abstract][Full Text] [Related]
19. Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.
Katsanos A; Dastiridou AI; Fanariotis M; Kotoula M; Tsironi EE
J Ocul Pharmacol Ther; 2011 Feb; 27(1):67-71. PubMed ID: 21214361
[TBL] [Abstract][Full Text] [Related]
20. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
